134923-62-9

Basic information

• Product Name: N1-(2-Methoxyethyl)-N1-Methylbenzene-1,4-diaMine
• Synonyms: N1-(2-Methoxyethyl)-N1-Methylbenzene-1,4-diaMine;N1-(2-Methoxyethyl)-N1-methyl-1,4-benzenediamine
• CAS NO: 134923-62-9
• Molecular Formula: C₁₀H₁₆N₂O
• Molecular Weight: 180.24684
• Mol File: 134923-62-9.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 301.3±22.0 °C(Predicted)
• Appearance: /
• Density: 1.066±0.06 g/cm3(Predicted)
• PKA: 6.74±0.50(Predicted)
• CAS DataBase Reference: N1-(2-Methoxyethyl)-N1-Methylbenzene-1,4-diaMine(CAS DataBase Reference)
• NIST Chemistry Reference: N1-(2-Methoxyethyl)-N1-Methylbenzene-1,4-diaMine(134923-62-9)
• EPA Substance Registry System: N1-(2-Methoxyethyl)-N1-Methylbenzene-1,4-diaMine(134923-62-9)

Safety Data

• Hazardous Substances Data: 134923-62-9(Hazardous Substances Data)

Usage

General Description

N1-(2-methoxyethyl)-N1-methylbenzene-1,4-diamine, also known as 2-Methoxy-N-methyl-N-(2-methylphenyl)ethanamine, is a type of diamine compound. This chemical is commonly used in organic synthesis and in the production of pharmaceuticals and specialty chemicals. It has also been identified as a potential intermediate in the production of certain types of dyes and pigments. It is considered to be a relatively stable compound under normal conditions, but it should be handled and stored with caution due to its potential for toxicity and harmful effects if ingested, inhaled, or in contact with skin or eyes. Overall, N1-(2-methoxyethyl)-N1-methylbenzene-1,4-diamine has a range of industrial and research applications, but it requires careful handling and management to ensure safety and proper use.

Upstream product

• 350-46-9 4-Fluoronitrobenzene 
• 151951-34-7 N-(2-methoxyethyl)-N-methyl-4-nitroaniline 

Downstream Products

• 1008506-12-4 N′-(6-bromoquinazolin-2-yl)-N-(2-methoxyethyl)-N-methylbenzene-1,4-diamine 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AND USES THEREOF

The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease, and in some embodiments diseases or disorders related to the dysregulation of kinase such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, FLT3(D835Y), ITK, TEC, TXK, BTK, or JAK, and the respective pathways.

Discovery of orally active carboxylic acid derivatives of 2-phenyl-5-trifluoromethyloxazole-4-carboxamide as potent diacylglycerol acyltransferase-1 inhibitors for the potential treatment of obesity and diabetes

Diacylglycerol acyltransferase-1 (DGAT-1) is the enzyme that catalyzes the final and committed step of triglyceride formation, namely, the acylation of diacylglycerol with acyl coenzyme A. DGAT-1 deficient mice demonstrate resistance to weight gain on hig